Insulet Corp (NAS:PODD)
$ 177.53 1.96 (1.12%) Market Cap: 12.43 Bil Enterprise Value: 13.01 Bil PE Ratio: 61.01 PB Ratio: 16.94 GF Score: 84/100

Insulet Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 07:30PM GMT
Release Date Price: $252.72 (-5.70%)
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

Great. Good afternoon, and thank you again for joining us. Welcome to the, again, second day of the Morgan Stanley Healthcare Conference. I'm Cecilia Furlong, a medical device analyst here at Morgan Stanley. It's my pleasure to have Insulet with us today, CEO, Jim Hollingshead; CFO, Wayde McMillan.

Really quickly, just disclosures, please see morganstanley.com/researchdisclosures. With that, again, thank you both for being here today.

James R. Hollingshead
Insulet Corporation - President, CEO & Director

It's a pleasure. Thanks, Cecilia.

Questions & Answers

Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

And I guess to start, just kind of looking at how you're thinking about the business. You had an experience, I think, and would love to kind of hear your perspective, taking in what's traditionally viewed DME type of product and really layering in a lot more of technical component software, either

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot